Loading clinical trials...

5 Years Follow-up Evaluation of Deterioration Kidney Biomarkers of HIV Patients | Clinical Trials | Clareo Health

COMPLETEDPHASE4

5 Years Follow-up Evaluation of Deterioration Kidney Biomarkers of HIV Patients

5 Years Follow-up Evaluation of Deterioration Kidney Biomarkers of HIV Patients : HIVOL 2 Study.

NCT02667678•Centre Hospitalier Universitaire de Saint Etienne

View on ClinicalTrials.gov

Summary

Detailed Description

The aim of this study is to compare the biomarkers levels as IL-18, KIM-1 and Cystatin C for patients infected by HIV with failure in renal function at year 5. The main criterion will be a degradation of the glomerular filtration throughput measured. It will be compared to clinical scores of degradation risks of renal function for patients infected with HIV. From 2011 to 2013, researchers realized a study called HIVOL, on the diagnostic performance of GFR (Glomerular Filtration Rate) estimators in patients infected with HIV. It lead to a publication in AIDS, retaken in the rational of recommendations of Infectious Diseases Society of America for the Chronic Renal Diseases support for patients infected with HIV. 235 patients were involved, for everyone researchers have a GFR measure (by Iohexol plasmatic clearance) and urinary and plasma samples.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patient affiliated or entitled to a social security scheme
•Patient HIV infected
•Patient included in the HIVOL cohort with a GFR measure available
•Patients who have given their consent in writing

Exclusion Criteria

•Pregnant or lactating women
•Patients treated with metformin
•Patients with a known allergy, regardless the type of allergy
•Patients with a history of thyroid dysfunction
•Any biological anomaly in the selection, which in the opinion of the investigator, may indicate a contraindication to the patient's participation in this study
•Degradation recent (not older than three months) of renal function defined as the degradation of more than 25 % GFR.
•Estimated GFR of less than 15 mL / min / 1.73m2
•History of major immediate or delayed skin reaction known to the injection of iodinated contrast medium (OMNIPAQUE®)
•Manifest thyrotoxicosis
•Hypersensitivity to the active substance or to any of the excipients (OMNIPAQUE®)
+2 more criteria

Locations (1)

Chu Saint Etienne

Saint-Etienne, France

Key Dates

Start Date

February 8, 2016

Primary Completion Date

September 30, 2018

Completion Date

September 30, 2018

Last Updated

April 1, 2019

Enrollment

173

ACTUAL participants

Conditions

HIV

Interventions

Cohort HIVOL, patients infected by HIV

BIOLOGICAL

A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

NCT07071623

Human Immunodeficiency Virus (HIV)HIV Pre-Exposure Prophylaxis

View study

RECRUITINGPHASE2

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

NCT04929028

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 1, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

5 Years Follow-up Evaluation of Deterioration Kidney Biomarkers of HIV Patients

Inclusion Criteria

Exclusion Criteria

A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Thinking and Memory Problems in People With HIV

The LD Lync Study - Natural History Study of Lipodystrophy Syndromes

Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs

Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption